Onkologie. 2024:18(4):244-248 | DOI: 10.36290/xon.2024.050

Her2 negative metastatic gastric cancer

Marián Liberko^{1, 2}, Renata Soumarová^{1, 2}

¹ Onkologická klinika, 3. LF UK a FNKV, Praha

² 3. lékařská fakulta Univerzity Karlovy, Praha

In the vast majority of cases, gastric cancer is diagnosed at the metastatic stage. However, even patients who are diagnosed at earlier stages of the disease experience relapse in the form of systemic generalization. Treatment options for metastatic disease depend on a number of variables. At present, the unsurpassed minimum is testing for predictive markers (Her2, MMR, PD-L1 CPS). For Her2-negative tumors, chemotherapy alone has long been the standard of care. Advances in molecular biology, genetics, together with the development of immunotherapy have led to a change in therapeutic options for these patients. The aim of this article is to provide an overview of the current treatment options for Her2 negative metastatic disease across multiple lineages.

Keywords: metastatic gastric cancer, Her2 negative disease, chemotherapy, immunotherapy.

Accepted: October 1, 2024; Published: October 7, 2024  Show citation